insulin degludec

Popular insulin meets target in real-world studyNovo Nordisk’s DEVOTE study reveals interesting findings.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
FDA approves long-acting insulin drugsFDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.
Insulin degludec/insulin aspart offers good glycemic control with fewer injections than basal-bolus regimenInsulin degludec/insulin aspart (Ryzodeg, Novo Nordisk) administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.